Literature DB >> 12960001

Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway.

Rajan Singh1, Jorge N Artaza, Wayne E Taylor, Nestor F Gonzalez-Cadavid, Shalender Bhasin.   

Abstract

Testosterone supplementation increases skeletal muscle mass and decreases fat mass; however, the underlying mechanisms are unknown. We hypothesized that testosterone regulates body composition by promoting the commitment of mesenchymal pluripotent cells into myogenic lineage and inhibiting their differentiation into adipogenic lineage. Mouse C3H 10T1/2 pluripotent cells were treated with testosterone (0-300 nM) or dihydrotestosterone (DHT, 0-30 nM) for 0-14 d, and myogenic conversion was evaluated by immunocytochemical staining for early (MyoD) and late (myosin heavy chain II; MHC) myogenic markers and by measurements of MyoD and MHC mRNA and protein. Adipogenic differentiation was assessed by adipocyte counting and by measurements of peroxisomal proliferator-activated receptor gamma 2 (PPAR gamma 2) mRNA and PPAR gamma 2 protein and CCAAT/enhancer binding protein alpha. The number of MyoD+ myogenic cells and MHC+ myotubes and MyoD and MHC mRNA and protein levels increased dose dependently in response to testosterone and DHT treatment. Both testosterone and DHT decreased the number of adipocytes and down-regulated the expression of PPAR gamma 2 mRNA and PPAR gamma 2 protein and CCAAT/enhancer binding protein alpha. Androgen receptor mRNA and protein levels were low at baseline but increased after testosterone or DHT treatment. The effects of testosterone and DHT on myogenesis and adipogenesis were blocked by bicalutamide. Therefore, testosterone and DHT regulate lineage determination in mesenchymal pluripotent cells by promoting their commitment to the myogenic lineage and inhibiting their differentiation into the adipogenic lineage through an androgen receptor-mediated pathway. The observation that differentiation of pluripotent cells is androgen dependent provides a unifying explanation for the reciprocal effects of androgens on muscle and fat mass in men.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12960001     DOI: 10.1210/en.2003-0741

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  140 in total

Review 1.  Therapy of erectile dysfunction: potential future treatments.

Authors:  Nestor F Gonzalez-Cadavid; Jacob Rajfer
Journal:  Endocrine       Date:  2004 Mar-Apr       Impact factor: 3.633

2.  Testosterone inhibits transforming growth factor-β signaling during myogenic differentiation and proliferation of mouse satellite cells: potential role of follistatin in mediating testosterone action.

Authors:  Melissa Braga; Shalender Bhasin; Ravi Jasuja; Shehla Pervin; Rajan Singh
Journal:  Mol Cell Endocrinol       Date:  2011-11-25       Impact factor: 4.102

Review 3.  Androgens and skeletal muscle: cellular and molecular action mechanisms underlying the anabolic actions.

Authors:  Vanessa Dubois; Michaël Laurent; Steven Boonen; Dirk Vanderschueren; Frank Claessens
Journal:  Cell Mol Life Sci       Date:  2011-11-19       Impact factor: 9.261

Review 4.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

Review 5.  Circulating androgens in women: exercise-induced changes.

Authors:  Carina Enea; Nathalie Boisseau; Marie Agnès Fargeas-Gluck; Véronique Diaz; Benoit Dugué
Journal:  Sports Med       Date:  2011-01-01       Impact factor: 11.136

6.  Muscle-bound? A tissue-selective nonsteroidal androgen receptor modulator.

Authors:  Elizabeth M Wilson
Journal:  Endocrinology       Date:  2007-01       Impact factor: 4.736

7.  The clinical use of macro and surface electromyography in diagnosis and follow-up of endocrine and drug-induced myopathies.

Authors:  M A Minetto; A Rainoldi; J F Jabre
Journal:  J Endocrinol Invest       Date:  2007-10       Impact factor: 4.256

8.  Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells.

Authors:  S Benvenuti; I Cellai; P Luciani; C Deledda; S Baglioni; C Giuliani; R Saccardi; B Mazzanti; S Dal Pozzo; E Mannucci; A Peri; M Serio
Journal:  J Endocrinol Invest       Date:  2007-10       Impact factor: 4.256

9.  Nuclear receptor profile in calvarial bone cells undergoing osteogenic versus adipogenic differentiation.

Authors:  Flavia Q Pirih; Rosette Abayahoudian; David Elashoff; Farhad Parhami; Jeanne M Nervina; Sotirios Tetradis
Journal:  J Cell Biochem       Date:  2008-12-01       Impact factor: 4.429

Review 10.  The use of phosphodiesterase 5 inhibitors with concomitant medications.

Authors:  G Corona; E Razzoli; G Forti; M Maggi
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.